Low bioavailability steroids in inflammatory bowel disease: an old chestnut or a whole new ballgame?

References

• Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J 1954;2(4884):375-8
   PubMed Web of Science ®Google Scholar
• Mayberry JF, Lobo A, Ford AC, Thomas A. NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people. Aliment Pharmacol Ther 2013;37(2):195-203
   PubMed Web of Science ®Google Scholar
• Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn’s disease. Gut 1994;35(3):360-2
   PubMed Web of Science ®Google Scholar
• Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121(2):255-60
   PubMed Web of Science ®Google Scholar
• Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006;24(2):319-30
   PubMed Web of Science ®Google Scholar
• Papi C, Festa V, Leandro G, et al. Long-term outcome of Crohn’s disease following corticosteroid-induced remission. Am J Gastroenterol 2007;102(4):814-19
   Google Scholar
• Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther 2001;15(10):1515-25
   Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4(1):28-62
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6(10):991-1030
   PubMed Web of Science ®Google Scholar
• Orlando A, Armuzzi A, Papi C, et al. Italian Society of Gastroenterology; Italian Group for the study of inflammatory bowel disease. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis 2011;43(1):1-20
   PubMedGoogle Scholar
• Brattsand R. Overview of newer glucocorticosteroid preparations for inflammatory bowel disease. Can J Gastroenterol 1990;4:407
   Google Scholar
• Edsbäcker S, Andersson P, Lindberg C, et al. Liver metabolism of budesonide in rat, mouse, and man. Comparative aspects. Drug Metab Dispos 1987;5(3):403-11
   Google Scholar
• van Grunsven PM, van Schayck CP, Derenne JP, et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax 1999;54(1):7-14
   PubMed Web of Science ®Google Scholar
• Crompton G. A brief history of inhaled asthma therapy over the last fifty years. Prim Care Respir J 2006;15(6):326-31
   PubMedGoogle Scholar
• Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997;40(6):775-81
   PubMed Web of Science ®Google Scholar
• Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther 2007;26(1):21-9
   Google Scholar
• Sowmy C, Reddy CS. Colon specific drug delivery systems: a review on pharmaceutical approaches with current trends. J Global Trends Pharmaceut Sci 2013;4:3-1174-83
   Google Scholar
• Friend DR. Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 1998;12(7):591-603
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Bengtsson B, Larsson P, et al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment Pharmacol Ther 2003;17(4):525-36
   PubMed Web of Science ®Google Scholar
• Pena AS, Kolkman JJ, Greinwald R, et al. Pharmacokinetics after single and multiple oral dosing of budesonide pH-modified-release capsule in patients with distal ulcerative colitis. Proceedings of Falk Workshop on Topical Steroids in Gastroenterology and Hepatology; Berlin, Germany, 14 June 2003. Dignass A, Gross V, Buhr HJ, James OFW, editors. Kluwer Academic Publishers, Dordrecht, The Netherlands: p.30-6
   Google Scholar
• Greenberg GR, Feagan BG, Martin F, et al. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn’s disease. N Engl J Med 1994;331(13):836-41
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR United States Study Group. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn’s disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol 2002;97(7):1748-54
   Google Scholar
• Tromm A, Bungani I, Tomsová E, et al. International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 2011;140(2):425-34, e1
   PubMed Web of Science ®Google Scholar
• Thomsen OO, Cortot A, Jewell D, et al. International Budesonide-Mesalamine Study Group. A comparison of budesonide and mesalamine for active Crohn’s disease. N Engl J Med 1998;339(6):370-4. Erratum in N Engl J Med 2001;345(22):1652
   Google Scholar
• Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 1994;331(13):842-5
   Web of Science ®Google Scholar
• Gross V, Andus T, Caesar I, et al. German/Austrian Budesonide Study Group. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn’s disease. Eur J Gastroenterol Hepatol 1996;8(9):905-9
   PubMed Web of Science ®Google Scholar
• Campieri M, Ferguson A, Doe W, The Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Gut 1997;41(2):209-14
   PubMed Web of Science ®Google Scholar
• Bar-Meir S, Chowers Y, Lavy A, et al. The Israeli Budesonide Study Group. Budesonide versus prednisone in the treatment of active Crohn’s disease. Gastroenterology 1998;115(4):835-40
   PubMed Web of Science ®Google Scholar
• Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16(1):47-54
   PubMed Web of Science ®Google Scholar
• Papi C, Luchetti R, Gili L, et al. Budesonide in the treatment of Crohn’s disease: a meta-analysis. Aliment Pharmacol Ther 2000;14(11):1419-28
   PubMed Web of Science ®Google Scholar
• Kane SV, Schoenfeld P, Sandborn WJ, et al. The effectiveness of budesonide therapy for Crohn’s disease. Aliment Pharmacol Ther 2002;16(8):1509-17
   PubMed Web of Science ®Google Scholar
• Seow CH, Benchimol EI, Griffiths AM, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2008;3
   Google Scholar
• Greenberg GR, Feagan BG, Martin F, et al. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide as maintenance treatment for Crohn’s disease: a placebo-controlled, dose-ranging study. Gastroenterology 1996;110(1):45-51
   PubMed Web of Science ®Google Scholar
• Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn’s disease. A placebo controlled one year study. Gut 1996;39(1):82-6
   PubMed Web of Science ®Google Scholar
• Ferguson A, Campieri M, Doe W, Global Budesonide Study Group. Oral budesonide as maintenance therapy in Crohn’s disease-results of a 12-month study. Aliment Pharmacol Ther 1998;12(2):175-83
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Ecker KW, et al. The Budesonide Study Group. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn’s disease. Gut 1998;42(4):493-6
   PubMed Web of Science ®Google Scholar
• Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn’s disease: a placebo-controlled trial. Aliment Pharmacol Ther 2005;21(4):363-71
   PubMed Web of Science ®Google Scholar
• Hellers G, Cortot A, Jewell D, et al. The IOIBD Budesonide Study Group. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology 1999;116(2):294-300
   PubMed Web of Science ®Google Scholar
• Ewe K, Böttger T, Buhr HJ, German Budesonide Study Group. Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn’s disease: a multicentre randomized placebo-controlled trial. Eur J Gastroenterol Hepatol 1999;11(3):277-82
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Löfberg R, Feagan BG, et al. Budesonide for maintenance of remission in patients with Crohn’s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. Am J Gastroenterol 2005;100(8):1780-7
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009;(1
   Google Scholar
• Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn’s disease. Gut 2001;48(2):186-90
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn’s disease. Clin Gastroenterol Hepatol 2003;1(2):122-8
   PubMed Web of Science ®Google Scholar
• Löfberg R, Danielsson A, Suhr O, et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996;110(6):1713-18
   PubMed Web of Science ®Google Scholar
• Keller R, Stoll R, Foerster EC, et al. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther 1997;11(6):1047-52
   PubMed Web of Science ®Google Scholar
• Gross V, Bunganic I, Belousova EA, et al. 3 g mesalazine granules are superior to 9 mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial. J Crohns Colitis 2011;5(2):129-38
   PubMed Web of Science ®Google Scholar
• Kolkman JJ, Möllmann HW, Möllmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today (Barc) 2004;40:589-601
   PubMed Web of Science ®Google Scholar
• Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;(10
   Google Scholar
• Kornbluth A, Sachar DB; Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004;99(7):1371-785
   PubMed Web of Science ®Google Scholar
• Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005;11(5):421-7
   Web of Science ®Google Scholar
• Pastorelli L, Saibeni S, Spina L, et al. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2008;28(5):581-8
   Google Scholar
• Brunner M, Ziegler S, Di Stefano AF, et al. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation. Br J Clin Pharmacol 2006;61(1):31-8
   PubMed Web of Science ®Google Scholar
• D’Haens GR, Kovács A, Vergauwe P, et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J Crohns Colitis 2010;4(2):153-60
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Travis S, Moro L, et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012;143(5):1218-26
   PubMed Web of Science ®Google Scholar
• Travis SP, Danese S, Kupcinskas L, et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014;63(3):433-41
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Danese S, Ballard DE, et al. Efficacy of Budesonide MMx® 6 mg QD for the maintenance of remission in patients with ulcerative colitis: results from a phase III, 12 month safety and extended use study. Gastroenterology 2012;142(5 Suppl 1):S-564
   Web of Science ®Google Scholar
• Schoon EJ, Bollani S, Mills PR, et al. Matrix Study Group. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn’s disease. Clin Gastroenterol Hepatol 2005;3(2):113-21
   PubMed Web of Science ®Google Scholar
• Cino M, Greenberg GR. Bone mineral density in Crohn’s disease: a longitudinal study of budesonide, prednisone, and non-steroid therapy. Am J Gastroenterol 2002;97(4):915-21
   PubMed Web of Science ®Google Scholar
• Greenberg GR, Feagan BG, Martin F, et al. Canadian Inflammatory Bowel Disease Study Group. Oral budesonide for active Crohn’s disease. N Engl J Med 1994;331(13):836-41
   PubMed Web of Science ®Google Scholar
• Herfarth H, Gross V, Andus T, et al. German/Austrian Budesonide Study Group. Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn’s ileocolitis depending on disease activity and localization. Int J Colorectal Dis 2004;19(2):147-52
   PubMed Web of Science ®Google Scholar
• Rutgeerts PJ. Conventional treatment of Crohn’s disease: objectives and outcomes. Inflamm Bowel Dis 2001;7(Suppl 1):S2-8
   Google Scholar
• Fascì Spurio F, Aratari A, Margagnoni G, et al. Oral beclomethasone dipropionate: a critical review of its use in the management of ulcerative colitis and Crohn’s disease. Curr Clin Pharmacol 2012;7(2):131-6
   Google Scholar
• Steed KP, Hooper G, Ventura P, et al. The in vivo behaviour of a colonic delivery system: a pilot study in man. Int J Pharm 1994;112:199-206
   Web of Science ®Google Scholar
• Levine DS, Raisys VA, Ainardi V. Coating of oral beclomethasone dipropionate capsules with cellulose acetate phthalate enhances delivery of topically active antiinflammatory drug to the terminal ileum. Gastroenterology 1987;92(4):1037-44
   Google Scholar
• Campieri M, Adamo S, Valpiani D, et al. Oral beclomethasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003;17(12):1471-80
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, D’Arienzo A, et al. Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2002;16(6):1109-16
   PubMed Web of Science ®Google Scholar
• Papi C, Aratari A, Moretti A, et al. Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates. Dig Dis Sci 2010;55(7):2002-7
   Google Scholar
• Nunes T, Barreiro-de Acosta M, Nos P, et al. RECLICU Study Group of GETECCU. Usefulness of oral beclomethasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. J Crohns Colitis 2010;4(6):629-36
   Google Scholar
• Romano C, Famiani A, Comito D, et al. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J Pediatr Gastroenterol Nutr 2010;50(4):385-9
   Google Scholar
• Balzano A, Manguso F, Alberici M, van Assche G. Efficacy and safety of beclomethasone dipropionate gastro-resistant, prolonged release tablets in mild to moderate ulcerative colitis: the Beta study. J Crohns Colitis 2010;4:S53
   Google Scholar
• Astegiano M, Pagano N, Sapone N, et al. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn’s disease of mild-to-moderate activity or in remission: retrospective study. Biomed Pharmacother 2007;61(6):370-6
   Google Scholar
• Tursi A, Giorgetti GM, Brandimarte G, et al. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn’s disease: an open-label, budesonide-controlled, randomized study. Med Sci Monit 2006;12(6):PI29-32
   Google Scholar
• Prantera C, Rizzi M, Cottone M, et al. Beclomethasone dipropionate in Crohn’s ileitis: a randomised, double-blind trial. Dig Liver Dis 2011;43(6):459-64
   PubMedGoogle Scholar
• Rizzello F, Gionchetti P, Galeazzi R, et al. Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study. Adv Ther 2001;18(6):261-71
   Google Scholar
• Scottish Medicines Consortium. Available from: www.scottishmedicines.org.uk/files/beclomethasone_dipropionate__Clipper__FINAL_Amended_310807_for_website.pdf
   Google Scholar
• Bleecker ER, Meyers DA, Bailey WC, et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest 2012;142(2):320-8
   PubMed Web of Science ®Google Scholar
• Roberts JK, Moore CD, Ward RM, et al. Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther 2013;345(2):308-16
   PubMed Web of Science ®Google Scholar
• Ufer M, Dilger K, Leschhorn L, et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 2008;84(1):43-6
   PubMed Web of Science ®Google Scholar
• Gelbmann CM, Rogler G, Gierend M, et al. Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn’s disease. Eur J Gastroenterol Hepatol 2001;13(12):1431-7
   Google Scholar